generation run 2026-05-07
65 min completedmodel pipeline-v5plan not recordedrun/4eaf620b…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- structural_inference_blocked
Reproduce
- inputs
- 20 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | WebSearch | delta-10-THC discovered Fusion Farms California wildfire 2020 CBD conversion | 10 | 2 | Discovery narrative not in academic literature; industry sources and specialist magazine used |
| 2 | WebSearch | delta-10-THC legal status DEA scheduling United States | 10 | 2 | Legal status info not available in academic databases |
| 3 | PubMed | delta-10-tetrahydrocannabinol pharmacology | 4 | 4 | All directly relevant to delta-10-THC pharmacology, toxicity, and market context |
| 4 | ClinicalTrials.gov · absence | delta-10-tetrahydrocannabinol | 0 | — | — |
| 5 | PubChem · absence | delta-10-tetrahydrocannabinol | 0 | — | — |
| 6 | PubChem | delta10-THC | 1 | 1 | Confirmed chemical identity of delta-10-THC |
| 7 | WebFetch | — | 1 | 2 | Primary account of modern rediscovery of delta-10-THC |
| 8 | OpenAlex | delta-8 THC hemp cannabinoid Farm Bill adverse effects poison control | 8 | 4 | Contextually relevant to delta-10-THC's regulatory situation and market position |
| 9 | PubMed | minor cannabinoids psychoactivity drug discrimination mice binding CB1 | 2 | 1 | Wiley et al. 2024 directly measures CB1/CB2 binding affinities for delta-10-THC |
| 10 | OpenAlex | delta-10-THC tetrahydrocannabinol isomer cannabinoid | 10 | — | — |
| 11 | PubMed | Jarbe THC isomers pigeon discrimination 1988 delta-2 delta-3 | 1 | 1 | Verifying historical animal pharmacology reference cited in discovery narrative |
| 12 | PubMed | Wolf cannabinoid analogs cross-reactivity urine immunoassay 2023 | 2 | 2 | Essential for drug testing harm reduction guidance |
| 13 | WebSearch + WebFetch | delta-10-THC legal status UK EU Canada Australia | 5 | 3 | Establishes international legal context |
| 14 | PubMed | Burgess 2024 poison control delta-10 PMID 38686923 | 1 | 1 | Key adverse event data from US poison control centers |
| 15 | PubMed | PMID 37721987 | 1 | 1 | Most important primary source for delta-10-THC receptor pharmacology |
| 16 | PubMed + WebSearch | Wiley 2024 minor cannabinoids delta-10 drug discrimination CB1 binding | 1 | 1 | Second key primary source for delta-10-THC pharmacology; partial in vivo activity noted |
| 17 | DOI verification | Verify Srebnik 1984 and Haghdoost 2023 DOIs | 2 | 2 | Confirming citation accuracy for key papers |
| 18 | WebSearch | Srebnik 1984 base-catalysed cannabinoid isomerization Journal Chemical Society Perkin | 10 | 1 | Historical synthesis chemistry paper verified |
| 19 | WebSearch | delta-10-THC discovery Fusion Farms California wildfire 2020 | 10 | 2 | Modern rediscovery narrative |
| 20 | NCATS Inxight Drugs | delta-10-THC VHQ3W73P66 | 1 | 2 | SMILES and CAS number not found elsewhere; official NIH source |
| 21 | PubChem | CID 146639819 (6aR,9R)-delta-10-THC | 1 | 1 | Specific trans isomer (6aR,9R) - the more pharmacologically active and commercially prevalent form |
| 22 | WebSearch + WebFetch | delta-10-THC urine drug test cross-reactivity immunoassay Wolf 2023 | 10 | 2 | Drug testing data essential for harm reduction section |
| 23 | OpenAlex | Huang comprehensive cannabinoid profiling acid-treated CBD delta-8 THC isomers byproducts | 2 | 1 | Analytical chemistry of CBD conversion byproducts - directly applicable to delta-10-THC manufacturing |
54 claims by section — every cited sentence, checked against its source
safety15 · 9 ok
Claim in safety — inconclusiveinconclusiveworking →
Δ10-THC is increasingly present in cannabis e-cigarette productssupported
Discusses emergence of novel cannabinoids including delta-8 and delta-10-THC in e-cigarette products. acs.chemrestox.1c00290
Δ10-THC is increasingly present in cannabis e-cigarette productssupported
Review examining pharmacology, toxicity, potential therapeutic uses and health risks of delta-8/10-THC and other hemp-derived cannabinoids; addresses public health consequences of vaping. j.toxrep.2026.102202
This process is known to generate unknown iso-THC isomers and hydrated THC byproducts, residual solvents, heavy metals, and reaction byproducts from inadequate purification, and significant discrepancies between declared and actual cannabinoid concentrations on certificates of analysispartially supported
CBD acid-treatment generates delta-8, delta-9-THC, and other iso-THC isomers as byproducts. Commercial edibles showed overclaimed delta-8, excessive delta-9, and undeclared iso-THC isomers. j.foodchem.2023.138187
This process is known to generate unknown iso-THC isomers and hydrated THC byproducts, residual solvents, heavy metals, and reaction byproducts from inadequate purification, and significant discrepancies between declared and actual cannabinoid concentrations on certificates of analysispartially supported
NMR, HPLC, and MS analysis of 10 delta-8 THC products found impurities far beyond declared CoA levels. Products synthesized from CBD contain concerning unknown-effect impurities. molecules27206924
This process is known to generate unknown iso-THC isomers and hydrated THC byproducts, residual solvents, heavy metals, and reaction byproducts from inadequate purification, and significant discrepancies between declared and actual cannabinoid concentrations on certificates of analysispartially supported
NMR, HPLC, and MS analysis of 10 delta-8 THC products found impurities far beyond declared CoA levels. Products synthesized from CBD contain concerning unknown-effect impurities. molecules27206924
Claim in safety — not_supportednot supportedworking →
Claim in safety — inconclusiveinconclusiveworking →
Vanegas et al. (2022) demonstrated in mice that Δ8-THC produces tolerance via CB1 receptor downregulation, cross-tolerance to the synthetic cannabinoid WIN 55,212-2, and rimonabant-precipitable physical dependencesupported
Delta-8-THC produces tolerance (via CB1 downregulation), cross-tolerance to WIN 55,212-2, physical dependence signs after rimonabant-precipitated withdrawal. j.drugalcdep.2022.109640
Cannabis more broadly carries moderate abuse and dependence risk with a 2–6 day withdrawal syndrome characterized by irritability, sleep disruption, appetite changes, and craving.supported
Delta-9-THC has moderate reinforcing effects; cannabis has 2-6 day withdrawal syndrome. fpsyt.2024.1322434
Claim in safety — inconclusiveinconclusiveworking →
CYP-mediated interactions: By structural analogy to Δ9-THC, Δ10-THC is presumed to undergo hepatic metabolism via CYP3A4 and CYP2C9supported
CYP metabolism to 11-OH-THC and 11-COOH-THC. 19.200
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Cross-reactivity with standard urine drug screens means that use may produce positive workplace drug test results regardless of impairment level.supported
All delta-10-THC chiral analogs cross-reacted with all 6 kits with varying selectivity. bkad059
summary6 · 3 ok
It binds CB1 with substantially lower affinity than Δ9-THC (IC₅₀ = 29.1 nM for the trans isomer versus 2.1 nM for Δ9-THC) and has not been characterized in controlled human studiessupported
Radioligand assay: CB1 IC50=29.1 nM (trans), 294.2 nM (cis); vs Δ9-THC IC50=2.1 nM. can.2023.0045
Claim in summary — inconclusiveinconclusiveworking →
Δ10-THC binds both CB1 (Ki = 63 nM) and CB2 (Ki = 28 nM) receptors, but its functional pharmacology at CB1 is uniquely antagonistic rather than agonistic — both the trans and cis isomers failed to produce agonist activity at concentrations up to 10 μM in vitro, instead blocking CB1 activation with antagonist IC₅₀ values of 460 nM and 1,040 nM, respectivelypartially supported
Study evaluating select minor cannabinoids and terpenes for Δ9-THC-like psychoactivity in mouse drug discrimination and CB1/CB2 receptor binding affinities. j.pnpbp.2024.110984
Δ10-THC binds both CB1 (Ki = 63 nM) and CB2 (Ki = 28 nM) receptors, but its functional pharmacology at CB1 is uniquely antagonistic rather than agonistic — both the trans and cis isomers failed to produce agonist activity at concentrations up to 10 μM in vitro, instead blocking CB1 activation with antagonist IC₅₀ values of 460 nM and 1,040 nM, respectivelypartially supported
Radioligand assay: CB1 IC50=29.1 nM (trans), 294.2 nM (cis); vs Δ9-THC IC50=2.1 nM. Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). can.2023.0045
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
neuroscience5 · 5 ok
Δ10-THC's demonstrated CB1 antagonist profile in vitro complicates direct application of this frameworksupported
Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). can.2023.0045
Entourage effect hypothesis: Δ10-THC is rarely consumed in isolation — commercial products frequently blend it with Δ8-THC, Δ9-THC, CBN, and other cannabinoidssupported
54% of products were blends containing 2-8 compounds. can.2023.0266
What is the true functional pharmacology in human neural tissue? The in vitro antagonist / in vivo partial substitutor discrepancy must be resolved in human-relevant systems before mechanism-based predictions are possible.supported
Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). First observation of antagonist property for any THC isomer. can.2023.0045
What is the true functional pharmacology in human neural tissue? The in vitro antagonist / in vivo partial substitutor discrepancy must be resolved in human-relevant systems before mechanism-based predictions are possible.supported
Study evaluating select minor cannabinoids and terpenes for Δ9-THC-like psychoactivity in mouse drug discrimination and CB1/CB2 receptor binding affinities. j.pnpbp.2024.110984
Does CB2 activation contribute to the subjective experience? The relatively high CB2 affinity (Ki = 28 nM) and emerging evidence of CB2 involvement in mood and reward processing raise the possibility that CB2, not CB1, is the relevant target.supported
Study evaluating select minor cannabinoids and terpenes for Δ9-THC-like psychoactivity in mouse drug discrimination and CB1/CB2 receptor binding affinities. j.pnpbp.2024.110984
pharmacology5 · 4 ok
The sole published in vitro receptor study (Haghdoost et al. 2023) revealed that both the trans and cis isomers bind CB1 but function as antagonists rather than agonists — neither isomer produced measurable agonist activity at concentrations up to 10 μM in cAMP and GTPγS functional assayssupported
Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). can.2023.0045
The trans isomer antagonized the CB1 agonist CP55,940 with an IC₅₀ of 460 nM; the cis isomer showed weaker antagonism (IC₅₀ = 1,040 nM)supported
both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). can.2023.0045
Claim in pharmacology — inconclusiveinconclusiveworking →
The only in vitro functional study demonstrates CB1 antagonist activity in both stereoisomerssupported
Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). First observation of antagonist property for any THC isomer. can.2023.0045
All parameters below are structural analog projections from Δ9-THC pharmacokinetics and must not be treated as measured values.supported
Review of cannabinoid pharmacokinetics: inhaled THC bioavailability 10-35%, peak 6-10 min, half-life 1-3 days occasional/5-13 days chronic users. CYP metabolism to 11-OH-THC and 11-COOH-THC. 19.200
chemistry4 · 4 ok
trans-Δ10-THC' — (6aR,9R) configuration. The more pharmacologically active isomer (CB1 IC₅₀ = 29.1 nM). This is the predominant isomer in commercial products and the form characterized in the Wiley et al. binding study (CB1 Ki = 63 nM; CB2 Ki = 28 nM).supported
Optimized synthesis of trans- and cis-Δ10-THC; crystal X-ray analysis confirmed structure. Radioligand assay: CB1 IC50=29.1 nM (trans). can.2023.0045
trans-Δ10-THC' — (6aR,9R) configuration. The more pharmacologically active isomer (CB1 IC₅₀ = 29.1 nM). This is the predominant isomer in commercial products and the form characterized in the Wiley et al. binding study (CB1 Ki = 63 nM; CB2 Ki = 28 nM).supported
Study evaluating select minor cannabinoids and terpenes for Δ9-THC-like psychoactivity in mouse drug discrimination and CB1/CB2 receptor binding affinities. Directly tests delta-10-THC among compounds assessed. j.pnpbp.2024.110984
cis-Δ10-THC' — (6aR,9S) configuration. Approximately 10-fold less active at CB1 (IC₅₀ = 294.2 nM).supported
Radioligand assay: CB1 IC50=29.1 nM (trans), 294.2 nM (cis). can.2023.0045
As a terpenophenolic cannabinoid sharing the C₂₁H₃₀O₂ framework with Δ9-THC, it is expected to be a viscous oil at room temperature, highly lipophilic, and poorly water-soluble. Δ8-THC is noted to be more chemically stable than Δ9-THC; the relative stability of Δ10-THC has not been characterizedsupported
Comprehensive review of delta-8-THC chemistry, pharmacology, and comparison to delta-9-THC. molecules29061249
history4 · 4 ok
Srebnik, Lander, Breuer, and Mechoulam demonstrated in 1984 that base-catalyzed isomerization of THC structures could shift the double bond to multiple ring positions, including the Δ10 position, yielding optically active Δ10-THC among other novel cannabinoidssupported
Describes base-catalyzed double-bond isomerization of cannabinoids, yielding various THC isomers including delta-10-THC. Provides synthetic route for cannabinoid double-bond migration. p19840002881
Haghdoost et al. reported in 2023 that a simplified KOᵗBu-based synthesis now permits scalable production of both trans and cis Δ10-THC isomers, replacing hazardous reagents.supported
Optimized synthesis of trans- and cis-Δ10-THC; crystal X-ray analysis confirmed structure. can.2023.0045
By 2023, Δ10-THC had become one of the six most prevalent intoxicating compounds in the US derived psychoactive cannabis products market, appearing in vapes, edibles, and blended formulationssupported
Delta-10-THC was among top 6 most prevalent intoxicating compounds across 26 identified. 54% of products were blends containing 2-8 compounds. can.2023.0266
This rapid market adoption occurred in the near-complete absence of pharmacological, toxicological, or clinical data — a pattern shared with Δ8-THC and other hemp-derived cannabinoids.supported
Thousands of US poison control calls among minors. No age restrictions. No synthesis regulations. add.16142
receptor-pharmacology4 · 3 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Notably, the CB2 Ki of 28 nM (95% CI: 17–46 nM) reported by Wiley et al. is higher than the CB1 Ki of 63 nM, yielding a CB1/CB2 selectivity ratio of approximately 2.3supported
Study evaluating select minor cannabinoids and terpenes for Δ9-THC-like psychoactivity in mouse drug discrimination and CB1/CB2 receptor binding affinities. j.pnpbp.2024.110984
The critical finding from Haghdoost et al. (2023) is functional, not binding: both trans- and cis-Δ10-THC failed to produce any measurable agonist response at CB1 in cAMP/GTPγS functional assays at concentrations up to 10 μMsupported
Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). can.2023.0045
The authors explicitly noted: "This functional property has not been previously observed for any other THC isomers".supported
First observation of antagonist property for any THC isomer. can.2023.0045
comparative-pharmacology3 · 2 ok
In the Wiley et al. (2024) mouse drug discrimination paradigm:supported
Study evaluating select minor cannabinoids and terpenes for Δ9-THC-like psychoactivity in mouse drug discrimination and CB1/CB2 receptor binding affinities. Directly tests delta-10-THC among compounds assessed. j.pnpbp.2024.110984
Δ8-THC produces CB1 receptor downregulation, cross-tolerance to WIN 55,212-2, and rimonabant-precipitable physical dependence in micesupported
Delta-8-THC produces tolerance (via CB1 downregulation), cross-tolerance to WIN 55,212-2, physical dependence signs after rimonabant-precipitated withdrawal. j.drugalcdep.2022.109640
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
legal-status3 · 2 ok
In the United States, the distinction between "hemp-derived" and "synthetically derived" cannabinoids adds a layer of legal ambiguity unique to the post-2018 Farm Bill regulatory environment.supported
Viewpoint discussing federal policy loophole allowing psychotropic cannabis products to be commercially marketed across US, including delta-8 and delta-10-THC. jama.2022.20620
Claim in legal-status — inconclusiveinconclusiveworking →
The regulatory trajectory across US states is toward increasing restriction of chemically converted cannabinoids .supported
Viewpoint discussing federal policy loophole allowing psychotropic cannabis products to be commercially marketed across US, including delta-8 and delta-10-THC. jama.2022.20620
pharmacokinetic-detail3 · 3 ok
The following projections are drawn entirely from Δ9-THC class pharmacology and must be treated as structural analog estimates, not empirical values.supported
Review of cannabinoid pharmacokinetics: inhaled THC bioavailability 10-35%, peak 6-10 min, half-life 1-3 days occasional/5-13 days chronic users. CYP metabolism to 11-OH-THC and 11-COOH-THC. 19.200
Δ10-THC cross-reacts with all six major commercial urine cannabinoid immunoassay screening kits (Abbott, Lin-Zhi, Thermo Fisher, Roche, Siemens) at both standard (50 ng/mL) and sensitive (20–25 ng/mL) cutoffssupported
All delta-10-THC chiral analogs cross-reacted with all 6 kits with varying selectivity. CBD and 7-COOH-CBD did not cross-react. bkad059
Preanalytical stability is a confound: Δ10-THC and its analogs degrade rapidly at 45°C regardless of pH, becoming undetectable in urine within 24 hours at that temperaturesupported
Parent analogs not detected after single day at 45°C. Acidic pH reduces carboxy acid analog responses. bkad061
clinical-evidence1 · 0 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
effects-overview1 · 1 ok
Its CB1 antagonist profile in vitro predicts effects qualitatively different from Δ9-THC — potentially stimulating rather than sedating, memory-sparing rather than amnestic, and appetite-neutral rather than orexigenicsupported
Both isomers FAILED to show agonist properties up to 10 μM; both acted as CB1 antagonists (IC50=460 nM trans, 1040 nM cis). can.2023.0045